Emmes, a contract research organization that recently acquired Essex Management, said it has plans to make more “medium to larger scale deals” in Europe and Latin America over the next two years.
Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company, and Essex Bio-Technology, a China-based bio-pharmaceutical company, announced positive data from their VISTA-2 study (NCT04206020) – a U.S. randomized, double-blind, vehicle-controlled study of SkQ1 as treatment for Dry Eye Disease (DED).